March 8 (Reuters) - Helix Biopharma Corp HBP.TO :
* Reports on advancement of its L-DOS47 phase I/II study in Poland
* Registration office of medicinal products in Poland and bioethics committee
approved an amendment to phase I/II study of L-DOS47
* Source text for Eikon
* Further company coverage HBP.TO